X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Pfizer with Strides Arcolab - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs STRIDES SHASUN LTD - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

STRIDES SHASUN LTD 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER STRIDES SHASUN LTD PFIZER/
STRIDES SHASUN LTD
 
P/E (TTM) x 24.6 14.1 174.4% View Chart
P/BV x 3.9 1.9 205.0% View Chart
Dividend Yield % 0.8 0.5 151.7%  

Financials

 PFIZER   STRIDES SHASUN LTD
EQUITY SHARE DATA
    PFIZER
Mar-16
STRIDES SHASUN LTD
Mar-16
PFIZER/
STRIDES SHASUN LTD
5-Yr Chart
Click to enlarge
High Rs2,7241,413 192.8%   
Low Rs1,611848 190.0%   
Sales per share (Unadj.) Rs440.9353.3 124.8%  
Earnings per share (Unadj.) Rs48.723.4 208.2%  
Cash flow per share (Unadj.) Rs75.841.0 184.9%  
Dividends per share (Unadj.) Rs15.005.00 300.0%  
Dividend yield (eoy) %0.70.4 156.4%  
Book value per share (Unadj.) Rs462.9320.4 144.5%  
Shares outstanding (eoy) m45.7589.35 51.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.93.2 153.7%   
Avg P/E ratio x44.548.3 92.1%  
P/CF ratio (eoy) x28.627.6 103.7%  
Price / Book Value ratio x4.73.5 132.7%  
Dividend payout %30.821.4 144.1%   
Avg Mkt Cap Rs m99,163100,988 98.2%   
No. of employees `0002.94.7 61.6%   
Total wages/salary Rs m2,7584,988 55.3%   
Avg. sales/employee Rs Th6,981.76,730.0 103.7%   
Avg. wages/employee Rs Th954.51,063.6 89.7%   
Avg. net profit/employee Rs Th771.1445.5 173.1%   
INCOME DATA
Net Sales Rs m20,17031,564 63.9%  
Other income Rs m8571,212 70.7%   
Total revenues Rs m21,02832,776 64.2%   
Gross profit Rs m4,3105,213 82.7%  
Depreciation Rs m1,2391,573 78.8%   
Interest Rs m51,803 0.3%   
Profit before tax Rs m3,9233,049 128.7%   
Minority Interest Rs m0127 0.0%   
Prior Period Items Rs m0-27 0.0%   
Extraordinary Inc (Exp) Rs m99-371 -26.7%   
Tax Rs m1,794689 260.6%   
Profit after tax Rs m2,2282,089 106.6%  
Gross profit margin %21.416.5 129.4%  
Effective tax rate %45.722.6 202.5%   
Net profit margin %11.06.6 166.8%  
BALANCE SHEET DATA
Current assets Rs m16,29935,949 45.3%   
Current liabilities Rs m7,59419,402 39.1%   
Net working cap to sales %43.252.4 82.3%  
Current ratio x2.11.9 115.8%  
Inventory Days Days6571 92.1%  
Debtors Days Days26127 20.3%  
Net fixed assets Rs m8,62234,478 25.0%   
Share capital Rs m458894 51.2%   
"Free" reserves Rs m20,72222,601 91.7%   
Net worth Rs m21,18028,632 74.0%   
Long term debt Rs m2527,455 0.1%   
Total assets Rs m29,13776,591 38.0%  
Interest coverage x755.52.7 28,073.4%   
Debt to equity ratio x01.0 0.1%  
Sales to assets ratio x0.70.4 168.0%   
Return on assets %7.75.1 150.8%  
Return on equity %10.57.3 144.1%  
Return on capital %19.08.2 232.5%  
Exports to sales %0.148.1 0.1%   
Imports to sales %17.514.5 120.9%   
Exports (fob) Rs m1215,192 0.1%   
Imports (cif) Rs m3,5264,565 77.2%   
Fx inflow Rs m5216,612 0.3%   
Fx outflow Rs m1405,292 2.6%   
Net fx Rs m-8811,320 -0.8%   
CASH FLOW
From Operations Rs m3,436717 479.5%  
From Investments Rs m-6,991-22,284 31.4%  
From Financial Activity Rs m-61929,488 -2.1%  
Net Cashflow Rs m-4,1748,073 -51.7%  

Share Holding

Indian Promoters % 0.0 27.7 -  
Foreign collaborators % 63.9 0.0 -  
Indian inst/Mut Fund % 7.5 37.8 19.8%  
FIIs % 4.9 8.6 57.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 25.9 91.5%  
Shareholders   85,207 56,241 151.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   BIOCON LTD  CADILA HEALTHCARE  SUVEN LIFE  DR. DATSONS LABS  WOCKHARDT LTD.  

Compare PFIZER With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Bank & Realty Stocks Rally(Closing)

Indian share markets surged further in the afternoon session and finished in the green for the second straight session on heavy buying in realty stocks, metal stocks and bank stocks.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Aug 23, 2017 (Close)

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS